Pharmaceutical benefits manager Humana has made a deal with Gilead Sciences to exclusively offer the company’s two newest hepatitis C virus (HCV) drugs, Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) for patients seeking treatment, Modern Healthcare reports.

The company’s announcement is the latest in a series of pricing wars between health insurers, pharmaceutical benefits managers and drug makers across the country.

Battles started back in December, when benefits manager Express Scripts announced it would give exclusive priority to AbbVie’s new Viekira Pak (ombitasvir/paritaprevir/ritonavir; dasabuvir) regimen, refusing to cover Gilead’s drugs.

Soon after, CVS Health and Anthem made deals with Gilead to prioritize its new HCV drugs over AbbVie’s. Prime Therapeutics will be covering all three treatments from both companies.

Currently, 12 weeks of Gilead’s Sovaldi and Harvoni treatments cost $84,000 and $94,500, respectively, at market price, and 12 weeks of Abbvie’s Viekira Pak costs $83,320. So far, none of the benefits managers has revealed the discounts they received.